Communiqués SynAct Pharma AB

Actions

SYNACT

SE0008241491

Produits pharmaceutiques

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 10/07/2026			Varia. 5j.	Varia. 1 janv.
21,80 ^SEK	+2,11%		+15,22%	-3,54%

09/07	Synact Pharma présente des données précliniques sur le resomelagon dans l'arthrose : le titre s'envole	FW
09/07	Synact Pharma : des résultats précliniques préliminaires démontrent que le resomelagon réduit l'inflammation et les lésions articulaires liées à l'arthrose	FW

Communiqués

09/07	Resomelagon shows reduced inflammation and joint damage in osteoarthritis model	AQ
02/07	SynAct Pharma : Company presentation	PU
02/07	SynAct Pharma : Bolagspresentation	PU
29/06	BIO International USA confirms growing interest in resomelagon and SynAct Pharma following the positive effects of the ADVANCE study	AQ
16/06	SynAct Pharma: Updated Base Case after ADVANCE	AQ
15/06	SynAct Pharma (Interview): ADVANCE Topline Data	AQ
15/06	SynAct Pharma: 40mg Best Dose in ADVANCE	AQ
15/06	SynAct Pharma Board of Directors and Management Enter Lock-up Agreements	AQ
15/06	SynAct Pharma : Phase 2b ADVANCE study demonstrates positive effects of resomelagon in Rheumatoid Arthritis - supports phase 3 design, regulatory interactions, and partnering	PU
15/06	Phase 2b ADVANCE study demonstrates positive effects of resomelagon in Rheumatoid Arthritis – supports phase 3 design, regulatory interactions, and partnering	AQ
12/06	SynAct obtains key US patent for resomelagon securing exclusivity until 2044	AQ
11/06	Report from the 2026 Annual General Meeting of SynAct Pharma AB (publ)	AQ
27/05	SynAct Pharma publishes Q1 2026 interim results	AQ
26/05	Synact Pharma large shareholder trading update	AQ
19/05	SynAct Pharma to present at the BioStock Global Forum 2026 on May 21	AQ
07/05	Notice of annual general meeting in SynAct Pharma AB	AQ
06/05	SynAct Pharma completes dosing in phase IIb ADVANCE study ahead of June readout	AQ
06/05	SynAct Pharma completes dosing for last patient in Phase 2b ADVANCE study	AQ
05/05	SynAct Pharma to participate at the LSX Nordic Congress on May 19-20, 2026 in Copenhagen	AQ
27/04	What good data looks like: SynAct Pharma ahead of its ADVANCE readout	AQ
23/04	SynAct Pharma : Nomination Committee ahead of the 2026 Annual General Meeting	PU
23/04	SynAct Pharma’s Nomination Committee ahead of the 2026 Annual General Meeting	AQ
16/04	SynAct Pharma : Company presentation	PU
16/04	SynAct Pharma : Bolagspresentation	PU
15/04	SynAct Pharma publishes Annual Report 2025	AQ